Entera Bio Ltd. announced its financial results for the year ended December 31, 2025, reporting a net loss of $11.4 million and cash on hand expected to support operations through mid-Q3 2026. The company also provided key business updates, including the submission of a streamlined Phase 3 protocol for its lead osteoporosis candidate EB613 and progress on other pipeline programs.
Key takeaways
Net loss for the year ended December 31, 2025 was $11.4 million, or $0.25 per ordinary share.
Cash and cash equivalents were $14.9 million as of December 31, 2025, with cash on hand (excluding restricted cash) expected to support operations through the middle of the third quarter of 2026.
In March 2026, Entera submitted a streamlined Phase 3 protocol for EB613 to the FDA, with feedback anticipated in late April 2026 and study initiation planned for late 2026.
In February 2026, Entera and OPKO expanded their collaboration to co-develop the oral LA-PTH tablet for hypoparathyroidism (EB612), with each party holding a 50% ownership interest and expecting to file an IND in late 2026.
Research and development expenses were $6.0 million for the year ended December 31, 2025, an increase of $1.5 million from the prior year, primarily due to EB613 Phase 3 preparation and collaboration program costs.